Interestingly, combination of anti-PD-1 with BayK8644 was associated with an increased absolute number and percentage of TCRβ+ CD4+ RORγt+ T cells in TDLN (Figure S8I) and increased frequency of tumor-specific CD8+ T cells within the tumor microenvironment (Figure 6M) compared with anti-PD-1 monotherapy. Here, CD8A is linked to neoplasm.